All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Roche to invest $283m in new manufacturing facility in China
The new biologics manufacturing facility will focus on producing Vabysmo, a bispecific antibody used in treating eye diseases, to meet the increasing demand for innovative medicines in China
Verastem secures FDA approval for Avmapki Fakzynja Co-Pack
The combination, comprising avutometinib capsules and defactinib tablets, was approved under the FDA’s accelerated approval programme, for KRAS-mutated recurrent LGSOC
HAYA secures $65m funding to advance RNA-guided medicines
The financing will support the clinical development of HAYA’s lead candidate, HTX-001, aimed at treating heart failure, and expand its RNA-guided regulatory genome pipeline
Enhertu shows promise in Phase 3 HER2-positive breast cancer trial
The study showed a significant improvement in pathologic complete response (pCR) rates when Enhertu was followed by paclitaxel, trastuzumab, and pertuzumab (THP), compared to the standard of care in the neoadjuvant setting
BioVaxys, Sona Nanotech collaborate to develop cancer therapeutics
The collaboration will combine BioVaxys’ DPX Immune Educating Platform with Sona’s Targeted Hyperthermia Therapy (THT), which uses infrared light to treat solid tumours
AstraZeneca’s Calquence approved in EU for mantle cell lymphoma
With the European Commission (EC) approval, Calquence becomes the first and only Bruton’s tyrosine kinase (BTK) inhibitor authorised for first-line treatment of MCL in the EU.
Nuevocor secures $45m funding to develop cardiomyopathy drug
Nuevocor will use the funds for a first-in-human Phase 1/2 clinical trial of NVC-001, targeting patients with LMNA-related dilated cardiomyopathy (LMNA DCM), in Europe and the US.
Veraxa Biotech, OmniAb collaborate on bispecific ADC programme
The collaboration integrates OmniAb’s transgenic antibody discovery solutions with Veraxa’s proprietary antibody drug conjugate (ADC) linker technology to advance next-generation therapeutic discovery.
Boehringer Ingelheim, Datavant expand real-world evidence partnership
Boehringer Ingelheim will use Datavant’s privacy-preserving tokenisation and data connectivity technologies to enhance clinical development and launch strategies for additional clinical trials
AstraZeneca’s Breztri meets primary endpoints in Phase 3 asthma trials
The clinical trials confirmed the efficacy of Breztri in improving lung function compared to dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines.